Serevent Asthma Safety Signal Is Good News For Advair, GSK Says

Adverse event outcomes from a Serevent safety study could help GlaxoSmithKline in one of its key messages for Advair, CEO J.P. Garnier told analysts in New York City Feb. 13

More from Archive

More from Pink Sheet